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Introduction
Adherence is the extent to which a patient's behavior coincides with medical or prescribed health advice. 1 Patient medication adherence, or taking medications as prescribed, is considered to be a significant clinical issue. 2 The Study of Medication Adherence and the Therapeutic Alliance (SMARTA), an industry-sponsored study conducted by University of Pittsburgh School of Pharmacy, was a project intended to assess the relationship between the administration of two scales and medication adherence. In SMARTA, six pharmacists in a community pharmacy chain administered two brief scales originally developed for use in psychotherapy (the Outcome Rating Scale and the Session Rating Scale, or ORS and SRS, respectively) 3, 4 to patients presenting for Medication Therapy Management (MTM) services. Two hundred and one participants were enrolled in an initial session, and approximately 34% of participants received up to three MTM sessions where the scales were utilized. Results suggested that administration of the ORS and SRS in this context had a positive impact on patient medication adherence. 5 The purpose of this qualitative study, a secondary study of SMARTA, was to interview participating pharmacists in order to evaluate their thoughts about the use of the scales (which were a chief SMARTA procedure). As noted, the ORS and SRS were originally developed for use in behavioral healthcare and have not been used, to our knowledge, in a community
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2 pharmacy setting. Given the innovative nature of using these instruments in this clinical setting, we interviewed the participating pharmacists to understand how the use of the scales affected their clinical practice (if at all) and might be adopted and integrated as part of routine practice.
Before describing the qualitative study methods, results, and conclusions, we felt it would be helpful first to describe the instruments themselves and, second, ground the reader in the everyday application of the instruments the SMARTA pharmacists used in the project. Although some technical study procedures were involved in the "day-to-day" work (such as providing information to participants about informed consent), we will describe only the administration procedures after a participant (a pharmacist's patient) was enrolled in the project.
The SMARTA project
The ORS and SRS are two brief, four-question scales intended to measure participant self-report of general well-being outcomes and perception of the therapeutic alliance, respectively. The outcome constructs for the ORS are "Individual," "Interpersonal," "Social," and "Overall." The SRS constructs are "Relationship," Goals and Topics," Approach or Method" 1 and "Overall." The specific scale questions are presented in Table 1 . How would you rate how things were in today's session overall? 1 We slightly modified the Approach question on the SRS to reflect the clinical context of community pharmacy rather than behavioral health; thus, the Approach question was reworded to refer to a "pharmacist's" approach rather than a "therapist's" approach.
Pharmacists could avail themselves to two administration types for either or both instruments: written or oral (oral versions are presented above). For the written version, participants could complete a visual analog scale, where "negatively phrased" statements presented on the left and "positively phrased" statement presented on the right are separated by a 10 cm line. Participants read both the left and right hand statements and mark their scores with hash marks along the 10 cm continuum for each of the four questions. There are no numbers on the continuum; in order to score the instrument, the pharmacist uses a standard ruler to measure the hash mark to the nearest centimeter and notes the score (1cm=1, 2cm=2, etc.). For the oral version, pharmacists simply read the statements to the participants and participants provide oral responses on a scale from 1-10 (where 1 is worst and 10 is best). Each instrument has a total score of 40, each with a significant clinical indicator described below. Prior to implementation, pharmacists received a one hour phone training/webinar on the theory, administration, and interpretation scales.
For study purposes, pharmacists were to administer the most appropriate version (written or oral) of the ORS at the beginning of an MTM session, and the most appropriate version of the SRS at the end of an MTM session (in this context, an MTM session was defined as an interaction where pharmacist and patient had the opportunity to communicate, for example, during a comprehensive medication review). For the ORS, pharmacists were to score the instruments "in the moment" and use the scores to guide to the MTM session. The ORS has a cutoff point of 25, meaning that any total scale score below 25 is a prompt for the provider to develop a discussion with the participant. For example, a participant may have rated three of the four ORS items with "7s" but rated the fourth item a "2," for an ORS scale score of 23. The pharmacist would then first invite the participant into a discussion, and, if the participant agreed, would inquire into the significance of that low score. (Specific instances of these interactions will be described in detail in the Results and Discussion sections). For the SRS, pharmacists could administer, score, and provide feedback on the scores within the last few moments of the MTM session, or score the instrument after the session and utilize the information during the subsequent session (if any). The SRS has a relatively higher cutoff point of 36, meaning that any score lower than 36 is also a prompt for the pharmacist to initiate discussion. For example, a participant may rate the pharmacist/session as "10" in three of the four items, but then provide a rating of "5" in the fourth item, for a total scale score of 35. The score would compel the pharmacist to solicit the participant's feedback on how to improve that score on that item for the next session.
Methods
The sample for this study was purposive and included the six community pharmacists who participated in SMARTA. The data collection method was a single-session, semi-structured interview, conducted by the principal author (M. Melczak) via telephone and tape-recorded. The interviews took place approximately 60 days after the end of SMARTA. Pharmacists were interviewed separately, not as part of a focus group. Pharmacists were provided with the semi-structured interview questions beforehand to prepare for the interview. The study was approved by the University of Pittsburgh IRB. Before actively participating in the interview, pharmacists were provided with an informational script satisfying University IRB consent procedures. The script described the study design and research procedures, the voluntary nature of the study, and the recording procedures. Participants then gave verbal consent to participate in the study. Even though the sample size was small, identifying information was redacted from any transcription, and confidentiality was stressed. Pharmacists were compensated for their participation in the interviews, which lasted approximately 30 minutes on average (range 15-35 minutes).
The questions for the semi-structured interview were based on key concepts from diffusion of innovation theory 6 and suggestions from the developer of the ORS and SRS. 7 While these questions appear to be fixed and finite, pharmacist responses often led to new questions or different ideas. Data were analyzed in terms of the guiding questions or interview-generated ideas through the use of a qualitative content analysis methodology.
Qualitative data can be analyzed in numerous ways. With qualitative content methods, data analysis can follow a systematic procedure. 8, 9 First, the original recorded communication was transcribed as closely to verbatim as possible, including both interviewee and interviewer statements. Then, each response, ending at each question, was reviewed to get an overall impression of the response. Participant responses were then approached as "meaning units"
10 in relation to the guiding interview question. Statements were then evaluated in terms of their degree of fit with the guiding question and presented as evidentiary extensions of the question domains. For example, one overarching domain of Question 1 was "concerns." Respondent statements that provided evidentiary support of these domains were included in results. Statements that did not support that domain were not included or included in other domains. Thus, the purpose of this methodology was not to derive a conceptual domain, but to evaluate statements with a degree of fit to those so given as guiding questions.
Results
Six pharmacists were interviewed (five female and one male). We did not ask for other demographic information. During transcription, one of the interviews was lost due to a technical malfunction; the pharmacist was not reinterviewed. The following results are from five pharmacist interviews. Pharmacist quotes are notated by a respective code (P1, P2, etc.). With regard to modification of the initial practice, one pharmacist derived a unique, abbreviated metric to evaluate individual "stress":
P1: I have taken this part of the study…and integrated it into my patient encounters at the clinic…I shortened it to one sentence and I give them numbers one through five.
This pharmacist's statement also demonstrates that while the philosophy underpinning the use of the scales is important, there are also perceived constraints in this process, such as limited time. Accordingly, while the original scales were also very brief and could be administered in a few minutes, further refining to one question suggests the pharmacist's perceived time constraint.
This same pharmacist also noted a "core element" in practice, which refers can be described a "vision" or "mission statement": 
Discussion
In SMARTA, we defined our innovation as the administration of the ORS and SRS within the context of community pharmacy MTM services. While pharmacists may have, to some degree, previously incorporated elements of patientcentered, outcome-informed care to their MTM practice, we are not aware of formalized systematic measurement of the particular outcomes advanced by the ORS and SRS, specifically measurement of therapeutic alliance within this clinical context. While our own lack of awareness should not be taken as an indication that such measurement does not exist, we are mostly confident that the formalized use of these scales in MTM practice could be described as an "innovative" practice.
Adoption and maintenance of an innovation depends on a number of factors, including the relative advantage of the innovation over old ways of doing "business," its compatability with existing values, experiences, and needs, its complexity (or, better said, simplicity), its trialability (the ability to experiment with the innovation for brief periods), and its observability (where the results of the innovation can be seen both individually in within a group or system).
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First, we see that participating pharmacists perceived there to be advantages to using the ORS and SRS. The advantages included: The (relatively) brief amount of clinical time it took to administer the scales. The identification of otherwise unknown (or uninvestigated) medication therapy management issues. The potential to positively impact medication adherence. The development of trust, which pharmacists correlated with the likelihood of adherence. The potential to positively impact quality of life.
Ease of asking questions.
In these perceived advantages, we note overlap with other factors for adoption of an innovation, such as simplicity (in both ease of asking questions and relatively short amount of time to ask questions). Given that this was a time-limited study, we may also state that this innovative practice afforded participating pharmacists with the chance to experiment with the innovation (trialability). We also note that one pharmacist was particularly enthusiastic about this intervention. Such a pharmacist might be considered to be an "early adopter" or an "innovation champion." 12 Such champions often lead the further development of innovative practices throughout their respective professional communities.
While there were perceived advantages, there are also perceived challenges to adoption.
Pharmacists received compensation for participating in the study but not afterwards. Pharmacists wanted to make sure the practice was worthwhile in terms of time and money. Although the innovation was perceived as "easy" and "brief," the perception of impact on time was still reported. Some pharmacists doubted about the effectiveness to the intervention without evidence. Some pharmacists had concerns about the use of the scales/the design of the scales with specific populations. Some pharmacists had initial anxiety, specifically with regard to patient emotionality or other serious personal issues. There was a clear concern about having a lack of training to deal with emotional issues, as well as the potential time costs emotional issues may take.
For some challenges, we believe that adoption of the innovative practice could be ameliorated through better training and education. Pharmacists received a one hour training prior to implementing the intervention, but it is likely that a more detailed training could reduce implementation anxiety. During training, we stressed, for example, that pharmacists were not expected to be "psychotherapists" but were encouraged to discuss any personal issues within the context of medication adherence. Furthermore, continued technical assistance and support would likely be beneficial to pharmacists should they implement this intervention in clinical practice.
For other challenges, there are larger systemic or institutional considerations, such as compensation for additional services. Finally, with the publication of the parent study, we hope that it provides pharmacists with at least preliminary evidence of the observability of the intervention and can begin to lay the foundation for future change in their pharmacy practice.
Conclusion
Pharmacists, in general, were receptive to participating in the original SMARTA study, which included the use of the ORS and SRS to measure patient outcomes and therapeutic alliance (with a distal goal of drawing correlation between the administration of these scales and medication adherence). Participation in the study encouraged pharmacists to reflect on their professional interactions with patients, and, for some, encouraged a shift in practice philosophy (i.e. take up a patient-centered stance). This shift was demonstrated by at least one pharmacist who noted the phrase, "They don't care how much you know until they know how much you care." Pharmacists had varying opinions on the degree to which their interactions could impact patient medication adherence, although they perceived other value and benefits secondary to the interactions, such as development of trust. While pharmacists did not maintain formal use of the scales after study end, they took away general principles of patient centered care and inquiry into aspects of life that may impact adherence.
